title: Type-1 cannabinoid receptors colocalize with caveolin-1 in neuronal cells.
abstract: Type-1 (CB1) and type-2 (CB2) cannabinoid receptors belong to the rhodopsin family of G protein-coupled receptors, and are activated by endogenous lipids termed "endocannabinoids". Recent reports have demonstrated that CB1R, unlike CB2R and other receptors and metabolic enzymes of endocannabinoids, functions in the context of lipid rafts, i.e. plasma membrane microdomains which may be important in modulating signal transduction. Here, we present novel data based on cell subfractionation, immunoprecipitation and confocal microscopy studies, that show that in C6 cells CB1R co-localizes almost entirely with caveolin-1. We also show that trafficking of CB1R in response to the raft disruptor methyl-beta-cyclodextrin (MCD) is superimposable on that of caveolin-1, and that MCD treatment increases the accessibility of CB1R to its specific antibodies. These findings may be relevant for the manifold CB1R-dependent activities of endocannabinoids, like the regulation of apoptosis and of neurodegenerative diseases.
authors: Department of Experimental Medicine and Biochemical Sciences, University of Rome Tor Vergata, 00133 Rome, Italy.
authors: Monica
authors: M
authors: Bari
authors: Sergio
authors: S
authors: Oddi
authors: Chiara
authors: C
authors: De Simone
authors: Paola
authors: P
authors: Spagnolo
authors: Valeria
authors: V
authors: Gasperi
authors: Natalia
authors: N
authors: Battista
authors: Diego
authors: D
authors: Centonze
authors: Mauro
authors: M
authors: Maccarrone
mesh_terms: D000818:Animals; D051242:Caveolin 1 / Q000378:metabolism*; D002458:Cell Fractionation / Q000379:methods; D045744:Cell Line, Tumor; D005910:Glioma / Q000473:pathology; D047468:Immunoprecipitation / Q000379:methods; D018613:Microscopy, Confocal / Q000379:methods; D021381:Protein Transport / Q000187:drug effects / Q000502:physiology; D051381:Rats; D043884:Receptor, Cannabinoid, CB1 / Q000378:metabolism*; D013997:Time Factors; D047392:beta-Cyclodextrins / Q000494:pharmacology
chemical_list: C495537:Cav1 protein, rat; D051242:Caveolin 1; D043884:Receptor, Cannabinoid, CB1; D047392:beta-Cyclodextrins; C108732:methyl-beta-cyclodextrin
references: Hepatology. 2003 Nov;38(5):1167-77
references: 14578855
references: Prog Neurobiol. 2007 Apr;81(5-6):349-79
references: 17276576
references: J Cell Sci. 2003 Dec 1;116(Pt 23):4739-49
references: 14600260
references: J Cell Biol. 2003 Nov 10;163(3):463-8
references: 14610053
references: J Biol Chem. 2004 Feb 13;279(7):5298-305
references: 14634025
references: Oncogene. 2004 Apr 29;23(20):3721-5
references: 15116103
references: Biochem J. 2004 Jun 1;380(Pt 2):435-40
references: 14979873
references: Synapse. 2004 Sep 15;53(4):208-13
references: 15266552
references: J Biol Chem. 2004 Aug 20;279(34):36013-21
references: 15210689
references: Biochem Biophys Res Commun. 2004 Nov 12;324(2):621-6
references: 15474472
references: J Biol Chem. 1996 Apr 19;271(16):9690-7
references: 8621645
references: Proc Natl Acad Sci U S A. 1997 Mar 18;94(6):2238-42
references: 9122178
references: J Biol Chem. 1998 Mar 6;273(10):5419-22
references: 9488658
references: J Neurochem. 1999 Aug;73(2):493-501
references: 10428044
references: Trends Immunol. 2005 Feb;26(2):97-103
references: 15668125
references: J Biol Chem. 2005 Mar 25;280(12):11641-7
references: 15659383
references: J Biol Chem. 2005 Apr 1;280(13):12212-20
references: 15657045
references: Annu Rev Biochem. 2005;74:411-32
references: 15952893
references: Neuromolecular Med. 2005;7(1-2):37-50
references: 16052037
references: Life Sci. 2005 Aug 19;77(14):1640-50
references: 15978630
references: Int J Dev Neurosci. 1999 Nov;17(7):705-14
references: 10568687
references: Nat Med. 2000 Mar;6(3):313-9
references: 10700234
references: J Biol Chem. 2000 May 5;275(18):13484-92
references: 10788462
references: J Biol Chem. 2000 Dec 29;275(52):41447-57
references: 11006286
references: Mol Pharmacol. 2001 May;59(5):955-9
references: 11306675
references: Nat Rev Mol Cell Biol. 2000 Oct;1(1):31-9
references: 11413487
references: Blood. 2001 Dec 15;98(13):3860-3
references: 11739199
references: Trends Mol Med. 2002 Feb;8(2):58-61
references: 11815270
references: Glia. 2002 Mar 1;37(3):275-90
references: 11857686
references: J Biol Chem. 2002 May 31;277(22):19876-81
references: 11909856
references: Nat Med. 2002 Jun;8(6):547-50
references: 12042794
references: Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10819-24
references: 12136125
references: J Clin Invest. 2002 Sep;110(5):597-603
references: 12208858
references: J Biol Chem. 2002 Sep 13;277(37):34280-6
references: 12097322
references: J Lipid Res. 2003 Apr;44(4):655-67
references: 12562849
references: Neuroscience. 2003;119(2):481-96
references: 12770562
references: J Neurochem. 2003 Jun;85(6):1468-79
references: 12787066
references: Cell Mol Life Sci. 2003 Jun;60(6):1200-8
references: 12861385
references: J Leukoc Biol. 2003 Oct;74(4):486-96
references: 12960289
references: Nat Rev Cancer. 2003 Oct;3(10):745-55
references: 14570037
references: Life Sci. 2005 Aug 19;77(14):1625-39
references: 15993425
references: Science. 2005 Oct 14;310(5746):329-32
references: 16224028
references: FEBS Lett. 2005 Nov 21;579(28):6343-9
references: 16263116
references: Curr Drug Targets CNS Neurol Disord. 2005 Dec;4(6):685-96
references: 16375686
references: Mini Rev Med Chem. 2006 Mar;6(3):257-68
references: 16515464
references: Trends Pharmacol Sci. 2006 Mar;27(3):134-40
references: 16476494
references: Handb Exp Pharmacol. 2005;(168):53-79
references: 16596771
references: Behav Brain Res. 2006 Sep 15;172(1):24-32
references: 16750274
references: Mol Pharmacol. 2006 Oct;70(4):1298-306
references: 16822929
references: J Immunol. 2006 Oct 15;177(8):4971-80
references: 17015679
references: Cancer Res. 2006 Nov 15;66(22):10647-51
references: 17108100
references: Trends Cell Biol. 2006 Dec;16(12):631-9
references: 17064899
references: J Biol Chem. 2007 Feb 23;282(8):5934-43
references: 17190831
references: Nat Rev Neurosci. 2003 Nov;4(11):873-84
references: 14595399